Aurelien Rizk PhD

Aurélien Rizk is the co-founder and Chief Scientific Officer of InterAx Biotech, a biotechnology company advancing drug discovery through mathematical modeling, AI, computational chemistry, and cellular assays to identify optimal GPCR signaling profiles for efficacy and safety and create differentiated therapeutics. He specializes in computational models of cell signaling and GPCR pathways and has published over 15 papers on mathematical modeling of GPCR signaling. Aurélien completed postdoctoral research in 2015 at ETH Zurich and the Paul Scherrer Institute, earned his Ph.D. in computer science at INRIA in 2011, and previously co-founded Algorizk, a company delivering real-time physics simulations for education. He studied mathematics, physics, and computer science at the French Grande École Normale Supérieure de Cachan and works at the intersection of computational biology and innovative drug discovery.